JUL 27 2026
Otsuka Pharmaceutical — centanafadine
for ADHD
About
ADHD is a neurodevelopmental disorder that causes persistent inattention, hyperactivity, and impulsive behavior severe enough to interfere with daily life. Centanafadine works by balancing key brain chemicals involved in focus and impulse control. This mechanism could help manage core ADHD symptoms while potentially addressing common challenges like emotional regulation.
Pivotal trial
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on centanafadine
- Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - BioSpace
- Centanafadine Phase 3 Analyses Report Executive Function Gains in Adult ADHD - Patient Care Online
- Centanafadine for Treatment of ADHD in Children, Adolescents, and Adults Accepted By FDA for Priority Review - Pharmacy Times
- Otsuka preps for July decision on centanafadine for ADHD - pharmaphorum
- FDA accepts Otsuka’s centanafadine application for ADHD treatment - Pharmaceutical Technology